Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer

Minas P. Economides(NYU Langone Health), Harrys A. Torres(The University of Texas MD Anderson Cancer Center), Andreas Kyvernitakis(The University of Texas MD Anderson Cancer Center), Parag Mahale(National Cancer Institute), Terri Lynn Shigle(The University of Texas MD Anderson Cancer Center), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Aung Naing(The University of Texas MD Anderson Cancer Center), Francesco Turturro(The University of Texas MD Anderson Cancer Center), Jeff Hosry(The University of Texas MD Anderson Cancer Center)
Alimentary Pharmacology & Therapeutics
October 11, 2016
10.1111/apt.13825
Cited by 51

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
|Blood|1997|1.2k